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Abstract. Pregnancy in sickle cell disease (SCD) patients is associated with increased risk of maternal and fetal
mortality. This study determines pregnancy outcomes among women with SCD delivering at Korle-Bu Teaching Hospital,
Accra, Ghana. Nine hundred sixty (960) medical records of pregnant women (131 HbSS, 112 HbSC, and 717 comparison
group) from 2007 to 2008 were reviewed. The HbSS women were at increased risk of eclampsia (adjusted odds ratio
[AOR] = 10.56, 95% confidence interval [CI] = 3.60–30.96, P < 0.001), intrauterine growth restriction (AOR = 4.00, 95%
CI = 1.38–11.64, P = 0.011), and placenta previa (AOR = 22.03, 95% CI = 9.87–49.14, P < 0.001) compared with the
comparison group. The HbSC women had increased risk for intrauterine fetal death (AOR = 3.38, 95% CI = 1.15–9.96,
P = 0.027) and decreased risk of delivering low birth weight babies (AOR = 0.21, 95% CI = 0.06–0.73, P = 0.014). Women
with SCD in Ghana are at a greater risk of morbidity and mortality in pregnancy compared with women without hemoglobinopathies. Improved maternal and fetal outcomes in Ghanaian women with SCD can be achieved through effective
intervention by health care providers with thorough knowledge about predisposing factors toward adverse outcomes.

INTRODUCTION

focused on the risks to the fetus including preterm labor
and IUGR; however, there are limited data on the maternal
outcomes.5,11,15 Surprisingly, studies in Saudi Arabia and
Jamaica found a significantly higher rate of preeclampsia
and eclampsia in pregnancies complicated by SCD, even
though better pregnancy outcome was observed compared
with the studies conducted in Africa.16,17 The higher mortality rate among women with SCD in countries like Ghana
may be caused by inadequate healthcare support particularly
for pregnant women.18
In Ghana about 2% of neonates are affected by SCD
leading to 14,000 new cases annually.18 Currently, there is
no active management for SCD during pregnancy in Ghana
and this may be due to a lack of data on the pregnancy outcomes among women with SCD.18 Examining the possible
complications in pregnancy associated with SCD may provide insight into the management of SCD pregnancies in this
country. The purpose of this study was to identify association
between SCD and the occurrence of adverse maternal and
fetal outcomes that are associated with pregnancy at Korle-Bu
Teaching Hospital (KBTH), Accra, Ghana. Determining the
association of SCD to maternal and perinatal outcomes among
pregnant women will provide understanding of the unique
reproductive health burden of SCD on maternal and infant
health in Ghana, which may contribute to the basis for reducing the maternal and fetal mortality in the country. This
study is the first report of obstetric and pregnancy outcomes of
women with SCD in Ghana.

Sickle cell disease (SCD) is the most common monogenetic disorder worldwide, affecting an estimated 30 million
individuals and representing a major public health concern
because of its associated significant morbidity and mortality.1
Sickle cell disease occurs in individuals homozygous for the
bS globin gene (SS) or heterozygous for the bS allele and
different abnormal b globin gene alleles, such as bC (SC),
Sb0 thalassemia, or Sb+ thalassemia.2 Pregnant women with
SCD are known to be at high risk of obstetrical complications and perinatal mortality as well as sickle-related complications.3–5 The maternal and fetal complications include
prepartum and postpartum painful crises, pulmonary complications, anemia, preeclampsia, eclampsia, premature delivery
with associated risks, and intrauterine growth restriction
(IUGR).5–9 In developed countries, SCD pregnancies have
better outcomes because of improvements in active SCD
management throughout the pregnancy.2,4,10,11 However, even
though sub-Saharan countries such as Ghana and Nigeria have
a high prevalence of SCD and maternal mortality rates
exceeding 9% such improvements are yet to be observed.7
Furthermore, lack of adequate management during pregnancy
is thought to be the major factor responsible for the poor
maternal and fetal outcomes among women with SCD in subSaharan countries compared with developed countries such as
Great Britain and the United States.9,12–15 Despite improved
management in SCD pregnancies, higher rates of cesarean
delivery and mortality have been observed among women
with SCD in the United States population.5
Pregnant SCD women are at an increased risk of sickle cell
crisis, urinary tract infections, gestational diabetes, pneumonia, and anemia.12 Several studies on SCD pregnancy have

METHODOLOGY
This retrospective cohort study identified pregnancies
among women with SCD (HbSS or HbSC genotypes) who
received prenatal care and gave birth at the department of
obstetrics and gynecology at KBTH, Accra, Ghana compared
with pregnancies among women without any hemoglobinopathies (comparison). After ethical approval from Morehouse
School of Medicine Institutional Review Board for human
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subject research and Ghana Health Service ethical review
committee, a review was made of all available medical
records of women delivering at the department of obstetrics
and gynecology between January 2007 and December 2008
for prenatal and postnatal information. The exclusion criteria
were women < 18 years of age, non-singleton pregnancies,
incomplete or unavailable medical records, and presence of
co-morbidities such as malaria or human immunodeficiency
virus (HIV)/acquired immunodeficiency syndrome (AIDS).
Hemoglobin genotypes were characterized by acid-agar electrophoresis. The genotypes were characterized as HbSS
and HbSC, and women with no hemoglobinopathies were
characterized as a comparison group. The following information was recorded for each woman: age, gravidity (number of
pregnancies), and parity (number of birth with a gestational
age of 24 weeks or more). Obstetric outcomes measured
were gestational age at delivery, mode of delivery, preterm
delivery (defined as a delivery < 37 weeks), premature rupture
of membrane (PROM), antepartum hemorrhage (APH), gestational diabetes, intrauterine growth restriction (IUGR),
cephalopelvic disproportion (CPD), pregnancy-induced
hypertension (PIH), placenta previa, intrauterine fetal
death (IUFD), intrapartum stillbirth, preeclampsia, and
eclampsia. Perinatal outcomes included: birth weight (low
birth weight [LBW] defined as birth weight < 2.5 kg), fetal
heart rate, complications, and mortality. The SCD-related
complications were also recorded. The following are the definitions of the measured outcomes; PROM – breaking of the
membranous sac that surrounds the fetus (amniotic sac)
before labor; APH – bleeding from the vagina during pregnancy from the 24th week gestational age to term; gestational
diabetes –condition in which women without previously diagnosed diabetes exhibit high blood glucose levels during pregnancy; IUGR – poor growth of a baby while in the mother’s
womb during pregnancy; CPD – when a baby’s head or body
is too large to fit through the mother’s pelvis; PIH – high
blood pressure during pregnancy; preeclampsia – condition in
which high blood pressure and protein in the urine develop
after the 20th week of pregnancy; eclampsia – seizures (convulsions) in a pregnant woman that are not related to a
preexisting brain condition; placenta previa – complication of
pregnancy in which the placenta grows in the lowest part of
the womb (uterus) and covers all or part of the opening to the
cervix; IUFD – fetal deaths that occur after 28 weeks gestation
and the fetus weighs more than 500 g; intrapartum stillbirth –
a baby born dead without signs of skin disintegration or maceration and the death is assumed to have occurred < 12 hours
before delivery.
STATISTICAL ANALYSIS
Data entry and management was conducted using SPSS
software version 17.0 for Windows (SPSS Inc., Chicago, IL).
Data were analyzed with Stata version 9.2 (Stata Corp., College Station, TX). Chart extraction characteristics and effect
of SCD on pregnancy were compared using Pearson Chisquare (c2) or one-way analysis of variance where appropriate to determine statistical differences between the groups
of women (HbS and comparison). For instances in which
there were too few subjects per cell for the c2 test to be used,
Fisher’s exact test was used to compare discrete outcomes.
Multivariate logistic regression was used to determine the

odds ratio with 95% confidence of obstetrics outcomes. A
P value of £ 0.05 was considered significant for all analysis.
RESULTS
Study population. There were 18,488 deliveries including
multiple births such as twins and triplets made by 17,781 women
at the Obstetrics and Gynecology department of KBTH from
2007 to 2008 of which 253 (1.42%) were women with SCD.
There were 21 deaths among the women with SCD, which was
~7.2% of all maternal deaths. The mortality rate for women
with SCD was 83 deaths per 1,000 deliveries compared with a
mortality rate of 6.9 deaths per 1,000 deliveries for women
without any hemoglobinopathies. Following the selection
criteria, 960 antenatal records were selected of which 243 were
women with SCD (131 with HbSS and 112 with HbSC genotypes) and 717 randomly selected women without any hemoglobinopathy (comparison group) with a complete record to
match the SCD group in terms of age, gravidity, and parity.
The age distribution of the women ranged from 18 to 44 years
of age with a mean of 28.8 years. The majority of the women
were between 25 and 34 years of age. Women with SCD
(mean age, 27.7 years for HbSS and 27.8 years for HbSC)
were slightly younger than the comparison women with a
mean age of 29.1 years. This difference, although small, was
statistically significant (P < 0.001). About 56% of the women
were multigravidae (woman who has been pregnant more
than one time) and 44% were nulliparous (women who have
not given birth to a baby) (Table 1). A majority of the HbSS
women (58%) were primigravida (first time or have been
pregnant one time) and nulliparous (58%) compared with
comparison group (40.3%), P < 0.001. However, there were
no significant differences in gravidity and parity among HbSC
and comparison women (Table 1).
Antenatal and pregnancy-related complications. The major
complications that were present among the pregnant women
are shown in Table 2. Regarding hematologic complications,
anemia defined as hemoglobin < 11 g/dL, was present in 8.4%
of the HbSS pregnancies compared with 2.8% comparison
pregnancies (P < 0.001). However, anemia was not observed
among HbSC women. HbSS and HbSC women did not differ
Table 1
Characteristics of pregnant women at Korle-Bu Teaching Hospital
2007–2008
Variable

Age
Mean ± SD
18–24
25–34
³ 35
Gravidity
Primigravida
Multigravidae
Parity
Nulliparous
Primiparous
Multiparous

HbSS (N = 131)

HbSC (N = 112)

Comparison
group (N = 717)

27.7 ± 5.1*
38 (29.0%)*
80 (61.1%)*
13 (9.9%)*

27.8 ± 4.9†
32 (28.6%)†
69 (61.6%)†
11 (9.8%)†

29.1 ± 5.7
161 (22.5%)
407 (56.8%)
149 (20.8%)

76 (58.0%)*
55 (42.0%)*

53 (47.3%)
59 (52.7%)

284 (40.3%)
420 (59.7%)

76 (58.0%)*
29 (22.1%)*
26 (19.8%)*

53 (47.3%)
29 (25.9%)
30 (26.8%)

284 (40.3%)
190 (27.0%)
230 (32.7%)

Pearson c2 test adjusting for Yates correction for continuity where appropriate were used
to compare for statistical differences among the pregnant women. For instances in which
there were too few subjects per cell for the Pearson c2 test to be used, Fisher’s exact test was
used to compare discrete outcomes. Statistical significance was set at P £ 0.05. SCD = sickle
cell disease; SD = standard deviation.
*P < 0.001 HbSS vs. Comparison.
†P < 0.001 HbSC vs. Comparison.
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Table 2
Antenatal and pregnancy-related complications reported among
women delivering at Korle-Bu Teaching Hospital 2007–2008
Complications

HbSS (N = 131)

Hematologic
Anemia
11 (8.4%)*
Sickle cell crisis
12 (9.2%)
Infections
UTI
2 (1.5%)
Cellulitis
–
Pyelonephritis
1 (0.8%)
Pneumonia
1 (0.8%)
Pregnancy-related complications
APH
3 (2.3%)
Gestational diabetes
1 (0.8%)
IUGR
9 (6.9%)*
Eclampsia
13 (9.9%)*
Preeclampsia
10 (7.6%)*
CPD
6 (4.6%)
PIH
23 (17.6%)*†
PROM
18 (13.7%)*†
Placenta previa
26 (19.8%)*†
Meconium staining
1 (0.8%)

HbSC (N = 112)

Table 3
Logistic regression analysis of antenatal and pregnancy-related complications occurring at time of delivery among women with SCD
HbSS

Comparison
group (N = 717)
Diagnosis

–
7 (6.3%)

20 (2.8%)
–

2 (1.8%)
–
–
–

6 (0.8%)
1 (0.1%)
1 (0.1%)
2 (0.3%)

1 (0.9%)
–
2 (1.8%)
6 (5.4%)‡
7 (6.3%)
1 (0.9%)
4 (3.6%)
5 (4.5%)
2 (1.8%)
–

15 (2.1%)
7 (1.0%)
14 (2.0%)
7 (1.0%)
20 (2.8%)
22 (3.1%)
19 (2.6%)
15 (2.1%)
10 (1.4%)
8 (1.1%)

Pearson Chi-square ( c2) test adjusting for Yates correction for continuity where appropriate were used to compare for statistical differences among the pregnant women. For
instances in which there were too few subjects per cell for the Pearson c2 test to be used,
Fisher’s exact test was used to compare discrete outcomes. Statistical significance was set
at P £ 0.05. APH = antepartum hemorrhage; CPD = cephalopelvic disproportion; UTI =
urinary tract infection; IUGR = intrauterine growth restriction; PIH = pregnancy-induced
hypertension; PROM = premature rapture of membrane.
*P < 0.0001 HbSS vs. Comparison.
†P < 0.0001 HbSS vs. HbSC.
‡P < 0.001 HbSC vs. Comparison.

significantly in their SCD-related complications (Table 2).
There were 19 women in sickle cell crisis (12 HbSS and
7 HbSC). About 3% of the HbSS women had urinary tract
infection (UTI), pyelonephritis, or pneumonia and this is comparable with the comparison group. However, UTI is the
only infection that was observed among the HbSC women
(1.8%). The IUGR, eclampsia, preeclampsia, PIH, PROM,
and placenta previa rates were significantly higher among
HbSS women compared with the comparison group (P < 0.001)
(Table 2). However, complications such as APH, gestational
diabetes, CPD, and meconium staining were comparable
between the two groups (HbSS and comparison group). The
rate of eclampsia was higher in HbSC women (5.4%) compared with comparison group (1.0%), P < 0.001. The prevalence of PIH, PROM, and placenta previa were significantly
higher among HbSS women compared with HbSC women
(P < 0.0001). Although, the prevalence of other pregnancyrelated complications was lower among HbSC women compared with HbSS and the comparison group, the differences
were not significant (Table 2).
From the logistic regression analysis using the comparison
group as the reference group, pregnancy-related complications such as anemia (adjusted odds ratio [AOR] = 3.20,
95% confidence interval [CI] = 1.23–8.31, P < 0.017); preeclampsia (AOR = 5.58, 95% CI = 2.14–14.53, P < 0.001);
eclampsia (AOR = 10.56, 95% CI = 3.60–30.96, P < 0.001);
IUGR (AOR = 4.00, 95% CI = 1.38–11.64, P < 0.011); PIH
(AOR = 10.54, 95% CI = 4.94–22.47, P < 0.001); PROM
(AOR = 9.11, 95% CI = 4.06–20.45, P < 0.001); and placenta
previa (AOR = 22.03, 95% CI = 9.87–49.14, P < 0.001) were
associated with increased likelihood of occurrence in pregnant
HbSS women (Table 3). However, there were no significant
associations of APH, CPD, gestational diabetes, or meco-

AOR

95% CI

APH
1.79 0.43–7.40
Anemia
3.20 1.23–8.31
Preeclampsia 5.58 2.14–14.53
Eclampsia
10.56 3.60–30.96
CPD
1.14 0.33–3.97
IUGR
4.00 1.38–11.64
Gestational
0.39 0.02–6.71
diabetes
PIH
10.54 4.94–22.47
PROM
9.11 4.06–20.45
Placenta
22.03 9.87–49.14
previa
Meconium
0.12 0.00–33.72
staining

HbSC
P value

AOR

95% CI

P value

0.424
0.017
< 0.001
< 0.001
0.839
0.011
0.513

0.53
–
2.33
5.39
0.28
0.89
–

0.07–4.10
–
0.93–5.83
1.74–16.65
0.04–2.11
0.20–3.99
–

0.543
–
0.070
0.003
0.216
0.876
–

< 0.001 1.51 0.49–4.59
< 0.001 2.08 0.72–6.01
< 0.001 1.30 0.28–6.06
0.461

–

0.472
0.175
0.739

–

–

The adjusted odds ratio (AOR) and 95% confidence interval (CI) were obtained with
logistic regression in multivariate analyses adjusted for age, parity, and other variables in the
study. Statistical significance was set at P £ 0.05. Model I was used for the logistic regression
analysis. The reference for hypertension was pregnant women without hypertension, anemia
was pregnant women without anemia, eclampsia was pregnant women without eclampsia,
and that of intrauterine fetal death was women without intrauterine fetal death. APH =
antepartum hemorrhage; CPD = cephalopelvic disproportion; IUGR = intrauterine growth
restriction; PIH = pregnancy-induced hypertension; PROM = premature rapture of membrane.

nium staining with HbSS phenotype (Table 3). Interestingly,
eclampsia was the only pregnancy-related complication that
was associated with HbSC phenotype (AOR = 5.39, 95% CI =
1.74–16.65, P < 0.003); however, the risk is lower than for the
HbSS phenotype (Table 3).
Maternal and perinatal outcomes. Table 4 shows the maternal and perinatal outcomes among the women at KBTH.
There were a total of 884 live births (115 HbSS, 100 HbSC,
and 669 comparison group) in the study population (Table 4
and Figure 1). However, the rates were lower among HbSS
women (87.8%) compared with the comparison group
(93.3%), P = 0.028 (Figure 1). The occurrence of preterm
Table 4
Maternal and perinatal outcomes at Korle-Bu Teaching Hospital
2007–2008
Outcomes

HbSS

HbSC

No. of live births (n)
Gestational age*
Full-term birth
Preterm birth
Birth weight (kg)*
Mean ± SD
< 2.5
³ 2.5
Fetal heart rate*
Mean ± SD
Complication*
NICU
Grunting respiration
Asphyxia
Fetal distress
Mode of delivery*
Vaginal
Cesarean

115

100

669

85 (73.9%)
30 (26.1%)

78 (78.0%)
20 (20.0%)

485 (74.4%)
167 (25.6%)

3.0 ± 0.6
14 (12.2%)†
89 (77.4%)†

3.0 ± 0.7
3.0 ± 0.7
3 (3.0%)‡
92 (13.8%)
79 (79.0%)‡ 525 (78.5%)

130.1 ± 34.3

Comparison group

133.0 ± 31.7

135.0 ± 25.7

29 (25.2%)§
3 (2.6%)
3 (2.6%)
11 (9.6%)§

16 (16.0%)
–
3 (3.0%)
3 (3.0%)

100 (14.9%)
8 (1.2%)
10 (1.5%)
17 (2.5%)

59 (51.3%)§
56 (48.7%)§

51 (51.0%)‡ 448 (67.0%)
49 (49.0%)‡ 221 (33.0%)

Pearson Chi-square (c2) test adjusting for Yates correction for continuity where appropriate were used to compare for statistical differences among the pregnant women. For
instances in which there were too few subjects per cell for the Pearson c2 test to be used,
Fisher’s exact test was used to compare discrete outcomes. Statistical significance was set at
P £ 0.05. NICU = neonatal intensive care unit; IUFD = intrauterine fetal death; SD =
standard deviation.
*Live births only.
†P < 0.02 HbSS vs. HbSC.
‡P < 0.001 HbSC vs. Comparison.
§P < 0.001 HbSS vs. Comparison.
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Table 5
Logistic regression analysis of maternal and perinatal outcomes among
patients with SCD
HbSS

Figure 1. Birth outcomes at Korle-Bu Teaching Hospital 2007–
2008. Pearson Chi-square (c2) test adjusting for Yates correction for
continuity where used to compare for statistical differences among
different groups of birth outcomes. For instances in which there were
too few subjects per cell for the Pearson c2 test to be used, Fisher’s
exact test was used. Statistical significance was set at P £ 0.05. IUFD =
intrauterine fetal death.

delivery (birth at < 37 weeks gestation) and the mean birth
weight of infants delivered to the women were comparable
across the groups (Table 4). However, the prevalence of
LBW babies was lower among HbSC women (3.0%) compared with HbSS (12.2%) and comparison women (13.8%),
P < 0.05 (Table 4). There was no difference in the rate of
LBW deliveries between the HbSS and comparison groups.
In addition, there were higher rates of transfers of infants to
the neonatal intensive care unit (NICU) caused by fetal complications among the HbSS (25.2%) compared with comparison group (14.9%), P < 0.001 (Table 4). Furthermore, the
incidence of fetal distress was higher among infants delivered
to HbSS women (9.6%) compared with comparison group
(2.5%), P < 0.001 (Table 4). There were no significant differences across the groups with regard to fetal complications
such as grunting respiration and asphyxia. Nearly 50% of
both HbSS and SC women had cesarean section (CS) compared with 33% of the comparison group (P < 0.001), Table 4.
There were no significant differences between the groups
with regard to IUFD (Figure 1). However, the rates of
intrapartum stillbirth were higher among HbSS women
(10.7%) compared with comparison group (5.4%), P = 0.024
(Figure 1). Logistic regression analysis confirmed that HbSS
(AOR = 1.76, 95% CI = 1.20–2.68, P = 0.008) and HbSC
women (AOR = 2.60, 95% CI = 1.60–4.22, P < 0.001) were
more likely to undergo CS compared with comparison group
(Table 5). Infants delivered by HbSS women are more likely
to experience fetal distress (AOR = 3.26, 95% CI = 1.43–
7.44, P = 0.005). Additionally, HbSS (AOR = 2.43, 95%
CI = 1.23–4.82, P = 0.011) and HbSC women (AOR = 2.25,
95% CI = 1.04–4.90, P = 0.040) were more likely to experience intrapartum stillbirth and HbSC women (AOR = 3.38,
95% CI = 1.15–9.96, P = 0.027) were at an increased risk of
experiencing IUFD (Table 5). Interestingly, HbSC (AOR =
0.21, 95% CI = 0.06–0.73, P = 0.014) women had a reduced
risk of delivering LBW babies compared with the comparison group (Table 5).

HbSC

Diagnosis

AOR

95% CI

P value

AOR

95% CI

P value

Cesarean
Preterm birth
LBW
NICU
Grunting
respiration
Asphyxia
Fetal Distress
IUFD
Stillbirth

1.76
1.14
0.85
1.63
1.11

1.20–2.68
0.66–1.97
0.44–1.61
0.95–2.80
0.25–5.01

0.008
0.648
0.612
0.079
0.889

2.60
1.06
0.21
1.12
–

1.60–4.22
0.54–2.08
0.06–0.73
0.58–2.18
–

< 0.001
0.872
0.014
0.732
–

1.09
3.26
1.20
2.43

0.72–4.37
1.43–7.44
0.34–4.21
1.23–4.82

0.903
0.005
0.779
0.011

1.62
0.78
3.38
2.25

0.41–6.46
0.20–3.00
1.15–9.96
1.04–4.90

0.492
0.716
0.027
0.040

The adjusted odds ratio (AOR) and 95% confidence interval (CI) were obtained with
logistic regression in multivariate analyses adjusted for age, parity, and other variables in
the study. Statistical significance was set at P £ 0.05. Model I was used for the logistic
regression analysis. The reference for cesarean section was vaginal delivery. LBW = low
birth weight; NICU = neonatal intensive care unit.

DISCUSSION
It is well established that women with SCD have an
increased risk of maternal and fetal complications during
pregnancy compared with healthy women.11,19 In Africa, a
mortality rate of 7–12% persists7,13,20,21 as a result of SCD in
pregnancy, reflecting limited services and inadequate antenatal care.19 We report for the first time the outcome of pregnant women with SCD delivering at KBTH and compare
these outcomes with a comparison group of women with no
hemoglobinopathies. Unlike other studies in developed countries such as in the United States,11,15,22 this study indicates
that there is still a significantly higher maternal mortality
in women with SCD compared with women having no
documented hemoglobinopathies. The SCD mortality rate
was ~7.2% of all maternal mortality, which is similar to what
has been observed in other studies in Africa,7,13 suggesting
that in sub-Saharan Africa, the health of women with SCD is
severely compromised during pregnancy.
Pregnancy has been shown to exacerbate sickle cell crises5
and increase the rate of hospitalization. Recent study indicates that sickle cell crisis occurred in over 50% of the pregnant women with SCD.23 However, about 8% of sickle cell
crises were observed in this study, which is consistent with a
cooperative study conducted in the United States.11
Although the mechanisms for preterm delivery among
women with SCD remain unknown, several studies have
shown an increased risk of preterm delivery among women
with SCD.5,22,24,25 However, in the current study there were
no associations between SCD and preterm delivery. The CS
deliveries were more likely to be performed for pregnant
women with SCD than for the comparison group. The CS
deliveries are likely to be prearranged more often in SCD
because of fetal compromise and previous history. Closer
fetal monitoring and a lower threshold for tolerating abnormal fetal heart rate patterns, may also contribute to this
trend.5 The CS deliveries may also be performed as a result
of fetal distress, failure of labor to progress, or discretionary
repeated need for surgery. However, because of the retrospective nature of this study, differences between elective
and emergency CS deliveries could not be established. It is
known that women with SCD have increased risk of IUGR
(abnormally slow growth).3,6,16,19,20,22,26–28 In this study the
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occurrence of IUGR was higher among HbSS women than
HbSC and comparison women. In addition, HbSS women
were at increased risk of IUGR compared with comparison
women. This increased risk could be caused by chronic
maternal anemia and increased blood viscosity or degree of
sickling and vaso-occlusion in the placental circulation.27,29
Reduced oxygen content of blood in maternal anemia can
affect placental perfusion and thereby increase the risk of
IUGR.30 We did not observe associated risk of IUFD among
HbSS women. One explanation could be improved fetal
monitoring and the increased likelihood of interventions.5
However, there was an increased risk of IUFD among HbSC
women. The SCD women are more at risk of intrapartum
stillbirth compared with the comparison group. The pathological basis for an increased intrapartum stillbirth rate and
IUGR in women with SCD is unclear.16 Blockage of blood
flow caused by vaso-occlusion in the placenta may lead to
placental infarction and insufficient placental function affecting the supply of nutrients and metabolic exchange to the
growing fetus.16,31 In addition, the effect of chronic maternal
anemia and high incidence of PIH in SCD women may contribute to increased risk of intrapartum stillbirth.16
Urinary tract infection and placenta previa have been
reported as more common among women with SCD in some
studies but was not confirmed in this study.19,28 However,
incidence of PIH was high among HbSS women and they
were more at risk compared with the comparison group.
The HbSS women were at a greater risk of being anemic.
Anemia is one of the major complications of sickle cell
disease and may be caused by hemolysis or trapping of the
red blood cells in the spleen.30 Anemia in pregnancy has
been found to be associated with increased risk for PROM,
spontaneous preterm labor, preterm delivery, poor intrauterine growth, and LBW infants,32–38 which in turn results in
higher perinatal morbidity and mortality, and a higher infant
mortality rate.
Preeclampsia was higher for the HbSS group than among
the comparison group, which is consistent with previous
studies.39,40 The HbSS women were also more at risk of
preeclampsia, which was not observed among the HbSC
group. Eclampsia is an acute and life-threatening complication of pregnancy, characterized by the appearance of
tonic-clonic seizures, usually occurs in patients who have
developed preeclampsia41 and was observed 10 times more
among HbSS and 5 times more among HbSC women than
the comparison group. This finding is consistent with other
reports from the literature.5,6,42
SCD in pregnancy has been associated with LBW infants
and has been observed in 28–42% of cases in Jamaica19,43
and 38% of cases in the United States.11 Factors associated
with LBW among SCD mothers are varied and inconsistent but include lower gestational age, lower maternal
age, lower maternal weight, history of preeclampsia, history of acute anemic episodes, and a number of SCDrelated complications during pregnancy.11,19 In this study,
there was a lower incidence of LBW deliveries among HbSC
women compared with HbSS women and the comparison
group. Surprisingly, HbSC women had a reduced risk of delivering LBW babies. The higher rate of LBW babies among
HbSS women may be caused by lower maternal weight,
history of preeclampsia, and history of acute anemic episodes, which could be influenced by a high frequency of early

surgical delivery or premature induction, which are common
interventions in management of pregnancy among women
with SCD.31 Women with HbSS genotype are known to
have a higher incidence of abnormal velocimetry in the
uteroplacental circulation,44 which may be related to the
sickling process in the uteroplacental vessels and abnormally high blood viscosity.2 This is consistent with the persistence of higher rates of preeclampsia and LBW babies in
HbSS women.2
It is known that HbSC women have lower mortality and
morbidity rates than HbSS women.45,46 Pregnancy outcome
in HbSC disease is reported to be generally benign compared
with HbSS disease.2 In a Jamaican cohort study followed from
birth, pregnancy outcome in HbSC women did not differ from
that of the comparison group for the prevalence of preeclampsia.47 The study also found more live births and greater
birth weight in the HbSC women compared with HbSS
women. The current study shows better obstetrical outcomes
for HbSC women than HbSS women, which is consistent with
reported studies.47 There were no significant differences in
antenatal and pregnancy-related complications and pregnancy and fetal outcomes between HbSC women and the
comparison group, except for eclampsia, LBW babies (lower
in HbSC), and mode of delivery (number of cesareans). However, sickle-related complications were fewer for HbSC than
HbSS women.
We acknowledge that there are practical concerns limiting
our ability to fully interpret these results, in particular, the
retrospective chart review limited the nature and amount of
data collected and thus, the conclusions that can be drawn.
Complete data were unavailable for most of the pregnancies,
especially among comparison women, which could potentially
introduce some level of bias to the conclusions. Certainly a
retrospective cohort study of this nature, would often exclude
such details as close monitoring of SCD impact during pregnancy and/or fetal outcome after birth. However, the study
provides insights into the risk of complications that can burden pregnant women with SCD in Ghana. In addition, this
study illustrates how longitudinally linked data are useful for
assessing factors associated with adverse conditions such as
SCD. There is certainly need for a further detailed prospective study in this population.

CONCLUSION
This is the first study examining the effects of SCD on
pregnancy in Ghana. The study has identified association
between SCD and the occurrence of adverse maternal and
fetal outcomes that are associated with pregnancy at KBTH,
Accra, Ghana. These results raise concern about the quality
of medical care received by patients with SCD in Ghana.
Although further research is needed to understand the specific biologic mechanisms that contribute to SCD and adverse
pregnancy outcomes, there are current opportunities to improve
care to women with SCD through improved preconception
observation and counseling, education and prevention of highrisk behaviors, early and adequate prenatal care, and appropriate identification and treatment of pregnancy complications.
Comprehensive care may promote awareness of SCD among
affected women to present early for assessment and management of symptoms to medical and midwifery staff, who can
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provide continuity of care. This approach should result in early
identification and management of acute problems by the appropriate caregivers in the appropriate place.
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